Hoth Therapeutics Story

Is Hoth Therapeutics (NASDAQ:HOTH) a good mid run opportunity?
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Hoth Therapeutics. In general, we focus on analyzing Hoth Therapeutics stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Hoth Therapeutics's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Hoth Therapeutics's intrinsic value. In addition to deriving basic predictive indicators for Hoth Therapeutics, we also check how macroeconomic factors affect Hoth Therapeutics price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research. Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Hoth Therapeutics' stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Hoth Therapeutics in the context of predictive analytics.

Hype Prediction Details

Intrinsic Valuation Details

Naive Forecast Details

1 Analysts Consensus Details

Please note, it is not enough to conduct a financial or market analysis of a single entity such as Hoth Therapeutics. Your research has to be compared to or analyzed against Hoth Therapeutics' peers to derive any actionable benefits. When done correctly, Hoth Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Hoth Therapeutics.

How does Hoth Therapeutics Stands against Peers?

Analyzing Hoth Therapeutics competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Hoth Therapeutics across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be. Check out Hoth Therapeutics Competition Details

How Hoth Therapeutics utilizes its cash?

To perform a cash flow analysis of Hoth Therapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Hoth Therapeutics is receiving and how much cash it distributes out in a given period. The Hoth Therapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Hoth Therapeutics Net Cash Flow from Operations is most likely to decrease significantly in the upcoming years. The last year's value of Net Cash Flow from Operations was reported at (4.45 Million)

Acquisition by Linsley Wayne of 15000 shares of Hoth Therapeutics subject to Rule 16b-3

Legal trades by Hoth Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:

Hoth Therapeutics insider trading alert for grant of options by Linsley Wayne, the corporate stakeholder, on 23rd of July 2020. This event was filed by Hoth Therapeutics Inc with SEC on 2020-07-23. Statement of changes in beneficial ownership - SEC Form 4 [view details]

Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down Hoth Therapeutics Indicators

About Contributor